Matrix metalloproteinases and venous leg ulceration

European Journal of Dermatology

Volumn 10, Issue 3, 2000, Pages 173-180

  Herouy, Yared ^a   Trefzer, Dorothea ^a   Zimpfer, Ulrich ^a   Schöpf, Erwin ^a   Vanscheidt, Wolfgang ^a   Norgauer, Johannes ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chronic venous insufficiency; Metalloproteinase; Proteases; Venous ulcers; Wound healing

Indexed keywords

CALCIUM; CATHEPSIN B; CATHEPSIN G; CIPEMASTAT; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGENASE; EPIDERMAL GROWTH FACTOR; FIBRIN; FIBRINOGEN; FIBRONECTIN; GALARIDIN; HYDROXAMIC ACID DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 6; KALLIKREIN; LAMININ; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMIN; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; STROMELYSIN; TANOMASTAT; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ANGIOGENESIS; CUFF; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HYPERTENSION; LEG ULCER; LIPODERMATOSCLEROSIS; MOLECULAR DYNAMICS; PROTEIN DEGRADATION; PROTEINASE INHIBITION; REVIEW; STROMA CELL; WOUND HEALING;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; LEG ULCER; MATRIX METALLOPROTEINASES; SCLERODERMA, LOCALIZED; VENOUS INSUFFICIENCY; WOUND HEALING;

EID: 0034109348     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. 1. Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, Parks WC, Welgus HG. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest 1994; 94: 79-88.
2. 2. Vaalomo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kahari VM, Saarialho-Kere U. Distinct populations of stromal cells express collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109: 96-101.
3. 3. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998; 10: 602-8.
4. 4. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-35.
5. 5. Herrick SE, Sloan P, McGurk M, Freak L, McCollum CN, Ferguson MWJ. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 1992; 141: 1085-95.
6. 6. Browse ML, Burnand KG. The cause of venous ulceration. Lancet 1982; 2: 243-5.
7. 7. Coleridge Smith PD, Thomas P, Acurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J 1988; 296: 1726-7.
8. 8. Neumann HA, Van den Broek MJ. Increased collagen IV layer in the basal membrane area of the capillaries in severe chronic venous insufficiency. Vasa 1991; 20: 26-9.
9. 9. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999; 11: 614-21.
10. 10. Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 1994; 8: 823-31.
11. 11. Powell WC, Matrisan LM. Complex roles of matrix metalloproteinases in tumor progression. Attempts to understand metastasis formation. In: Gunther U, Schlag PM, Birchmeier W (eds). Metastasis related molecules. Springer-Verlag, Heidelberg, 1996; pp. 1-21.
12. 12. Seltzer JL, Jeffrey JJ, Eisen AZ. Evidence for mammalian collagenase as zinc ion metalloenzymes. Biochim Biophys Acta 1977; 485: 179-87.
13. 13. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
14. 14. Esteve PO, Tremblay P, Houde M, St-Pierre Y, Mandeville R. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta 1998; 1403: 85-96.
15. 15. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998: 466-71.
16. 16. Knäuper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544-50.
17. 17. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE. Cloning, expression and type II collagenolytic activity of matrix metalloproteinase. J Clin Invest 1996; 97: 761-8.
18. 18. Bini A, Wu D, Schnuer J, Kudryk BJ. Characterization of stromelysin 1 (MMP-3), Matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrinogen fragments D-Dimer and D-like monomer: NH (2)-terminal sequences of late-stage digest fragments. Biochemistry 1999; 38: 13928-36.
19. 19. Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996; 320: 659-64.
20. 20. Busiek DF, Ross FP, McDonnell S, Murphy G, Matrisian LM, Welgus HG. The matrix metalloproteinase matrilysin (PUMP) is expressed in developing human mononuclear phagocytes. J Biol Chem 1992; 267: 9087-92.
21. 21. Chandler S, Cossins J, Lury J, Wells G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumor necrosis factor-alpha fusion protein. Biochem Biophys Res Commun 1996; 228: 421-9.
22. 22. Cossins J, Dudgeon TJ, Catlin G, Gearing AJ, Clements JM. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem & Biophys Res Comm 1996; 228: 494-8.
23. 23. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez-Otin C. Indentification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281-6.
24. 24. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L, Murphy G. the activation of proMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDA form. J Cell Sci 1998; 111: 2789-98.
25. 25. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
26. 26. Vaalomo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kahari VM, Saarialho-Kere U. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109: 96-101.
27. 27. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Barbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. The EMBO J 1997; 16: 2319-32.
28. 28. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995; 270: 5331-8.
29. 29. Cao J, Sato H, Takino T, Seiki. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995; 270: 801-5.
30. 30. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44.
31. 30. Levy D, Lapierre F, Liang W, Ye W, Lange C, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K. Matrix metalloproteinase inhibitors: a structure activity study. J Med Chem 1998; 41: 199-223.
32. 31. Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinase-2 form is 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinase-2 and tissue inhibitor of metalloproteinase-1. Biochem J 1991; 278: 179-87.
33. 32. Wilde CG, Hawkins PR, Coleman RT, Levine WB, Delegeane AM, Okamoto PM, Ito LY, Scott RW, Seilhamer JJ. Cloning and characterization of human tissue inhibitor of metalloproteinases-3. DANN Cell Biol 1994; 13: 711-8.
34. 33. Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokha R, Schultz GA, Edwards DR. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4) cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997; 401: 213-7.
35. 34. Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2,-3 and -4) in normal and aberrant wound healing. Hum Pathol 1999; 30: 795-802.
36. 35. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72-and 92-kDa gelatinases by tissue inhibitors of metalloproteinase-2. J Biol Chem 1991; 266: 13070-5.
37. 36. Vowden K. Lipodermatosclerosis and atrophie blanche. J Wound Care 1998; 7: 441-3.
38. 37. Herouy Y, Schöpf E, Vanscheidt W. Lipodermatosclerosis. Phleb Digest 1998; 3: 6-8.
39. 38. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase in chronic leg ulcers. J Invest Dermatol 1996; 106: 1119-24.
40. 39. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64-8.
41. 40. Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, Schöpf E, Norgauer J, Vanscheidt W. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases. Implications for venous ulcer formation J Invest Dermatol 1998; 111: 822-7.
42. 41. Jarret PE, Burnand KG, Morland M, Browse NL Proceedings: Fibrinolysis and fat necrosis in the lower leg. Br J Surg 1976; 63: 157-60.
43. 42. Herouy Y, Nockowski P, Schöpf E, Norgauer J. Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration. Int J Mol Med 1999; 3: 511-5.
44. 43. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. Cell Biol 1997; 137: 1445-57.
45. 44. Sudbeck BS, Parks WC, Welgus HG, Pentland AP. Collagen-stimulated induction of keratinocyte collagenase is mediated via tyrosine kinase and protein kinase C activities. J Biol Chem 1994; 269: 30022-9.
46. 45. Sudbeck BD, Pilcher BK, Pentland AP, Parks WC. Modulation of intracellular calcium levels inhibits secretion of collagenase-1 by migrating keratinocytes. Mol Biol Cell 1997; 8:811-24.
47. 46. Herrick S, Ashcroft G, Ireland G, Horan M, McCollum C, Fergurson M. Upregulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab Invest 1997; 77: 281-8.
48. 47. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environment. Wound Rep Reg 1996; 4: 321-5.
49. 48. Gomis-Ruth F, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkow G. Mechanism of inhibition of human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997; 389: 77-81.
50. 49. Dhanaraj V, Ye QZ, Johnson L, Hupe D, Ortwine D, Dunbar JJr, Rubin J, Pavlovsky A, Humblet C, Blundell T. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996; 4: 375-86.
51. 50. Ye QZ, Hupe D, Johnson L. Catalytic domains of matrix metalloproteinases: a molecular biology approach to drug discovery. Curr Med Chem 1996; 3: 407-18.
52. 51. Beckett R, Whittaker M. Matrix metalloproteinase inhibitors. Exp Opin Ther Patents 1998; 8: 259-82.
53. 52. Levy D, Ezrin A. Matrix metalloproteinase inhibitor drugs. Emerg Drugs 1997; 2: 205-30.
54. 53. Hodgson J. Remodeling MMPIs. Biotechnology 1995; 13: 1531-4.
55. 54. Welgus HG, Jeffrey JJ, Eisen AZ. The collagen substrate specificity of human skin fibroblasts collagenase. J Biol Chem 1981 ; 256: 9511-5.
56. 55. Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. Collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987; 262: 10048-52.
57. 56. Hirose T, Patterson C, Pourmotabbed T, Mainardi CL, Hasty KA. Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity. Proc Natl Acad Sci 1993; 90: 2569-73.
58. 57. Knauper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, Zardi L, Murphy G. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997; 272: 7608-16.
59. 58. Seltzer JL, Akers KT, Weingarten H, Grant GA, McCourt DW, Eisen AZ. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with conformation using synthetic peptides. J Biol Chem 1990; 265: 20409-13.
60. 59. Mackay AR, Gomez DE, Cottam DW, Rees RC, Nason AM, Thorgeirsson UP. Identification of the 72-kDA (MMP-2) and 92-kDA (MMP-9) gelatinase/type IV collagenase in preparations of laminin and Matrigel. Biotechniques 1993; 15: 1048-51.
61. 60. Pourmotabbed T. Relation between substrate specificity and domain structure of 92 kDa type IV collagenase. Ann NY Acad Sci 1994; 732: 372-4.
62. 61. Bickett DM, Green MD, Wagner C, Roth JT, Berman J, McGeehan GM. A high throughput fluorogenic substrate for stromelysin (MMP-3). Ann NY Acad Sci 1994; 732: 351-5.
63. 62. Nagase H. Human stromelysins 1 and 2. Meth Enzymol 1995; 248: 449-70.
64. 63. Sanchez-Lopez R, Alexander CM, Behrendtsen O, Breathnach R, Werb Z. Role of zinc-binding-and hemopexin domain-encoded sequences in the substrate specificity of collagenase and stromelysin-2 as revealed by chimeric proteins. J Biol Chem 1993; 268: 7238-47.
65. 64. Noel A, Santavicca M, Stoll I, L'Hoir C, Staub A, Murphy G, Rio MC, Basset P. Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem 1995; 270: 22866-72.
66. 65. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, Seiki M. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immoblized on agarose beads. J Biol Chem 1998; 273: 16098-103.
67. 66. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16: 483-96.
68. 67. d'Orhto MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Membrane-type matrix metalloproteinase 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-7.
69. 68. Matsumoto S, Katoh M, Saito S, Watanabe T, Masuho Y. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Act 1997; 1354: 159-70.
70. 69. Kajita M, Kinoh H, Ito N, Takamura A, Itoh Y, Okada A, Sato H, Seiki M. Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: isolation of complemetary DANN clones for human and mouse mt4-mmp transcripts. FEBS Letters 1999; 475: 353-6.
71. 70. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999; 274: 8925-32.
72. 71. Imai K, Shikata H, Okada Y. Degradation of vitronectin by matrix metalloproteinase-1, -2, -3, -7 and -9. FEBS Letters 1995; 369: 249-51.
73. 72. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM. Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem 1997; 272: 18071-6.
74. 73. Chandler S, Cossins J, Lury J, Wells G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Com 1996; 228: 421-9.
75. 74. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez-Otin C. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281-6.